Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q2 FY26 results · Jul–Sep 2025
Procter & Gamble Health reported revenue from operations of ₹324.92 crore (up 3.7% from Q2 FY25) and net profit of ₹88.54 crore (up 7.5% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a standalone basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 324.92 | 313.41 | +3.7% | 338.74 | −4.1% |
| Other income | 4.95 | 3.28 | +50.9% | 4.03 | +22.8% |
| Total income | 329.87 | 316.69 | +4.2% | 342.77 | −3.8% |
| Profit before tax | 119.02 | 111.40 | +6.8% | 88.81 | +34.0% |
| Net profit for the period | 88.54 | 82.33 | +7.5% | 66.18 | +33.8% |
| EPS, basic (₹) | 53.34 | 49.60 | +7.5% | 39.87 | +33.8% |
| Net margin (%) | 27.2 | 26.3 | 19.5 |
Standalone
- Filed with BSE
- 05 Nov 2025, 17:35 IST
- Board meeting
- 05 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE